Shares of Neurocrine Biosciences (NBIX) soared 7.87% in Tuesday's trading session following the company's release of better-than-expected first-quarter 2025 financial results. The biopharmaceutical firm, known for its focus on neurological and endocrine disorders, reported earnings that surpassed analyst estimates and demonstrated robust sales growth for its lead product, INGREZZA.

Neurocrine reported adjusted earnings per share of $0.70 for Q1, significantly beating the analyst consensus estimate of $0.54. While this represents a 41.67% decrease from the $1.20 per share reported in the same period last year, it still impressed investors given the challenging market conditions. The company's quarterly revenue reached $572.6 million, a 11.12% increase year-over-year and exceeding the Street's forecast of $559.33 million.

The strong performance was primarily driven by INGREZZA, Neurocrine's treatment for tardive dyskinesia and chorea associated with Huntington's disease. INGREZZA net product sales for the quarter were $545.2 million, showing an 8% growth compared to the first quarter of 2024. The company also reaffirmed its full-year 2025 INGREZZA sales guidance of $2.50 billion to $2.60 billion, instilling confidence in investors about its continued growth trajectory. Additionally, Neurocrine reported encouraging initial sales of $14.5 million for CRENESSITY, its newly launched treatment for congenital adrenal hyperplasia.